Former Novartis pharmaceuticals chief David Epstein is going biotech
David Epstein is joining a long lineup of execs who are exchanging Big Pharma titles for a prominent place in the biotech world. The former Novartis pharmaceuticals chief is joining the biotech VC Flagship Pioneering as an executive partner, a new role at the trendsetting venture group.
Epstein’s first role as biotech entrepreneur will involve taking the chairman’s job at Rubius Therapeutics. And he’ll be playing an active role in Flagship’s other investments, which concentrate heavily on the axis of academic research and clinical work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.